Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.

Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.

This multicentre, phase II study of the Australian Lymphoma and Leukaemia Group (ALLG) and the Asian Myeloma Network (AMN) investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d; KTd) in patients with relapsed and/or refractory multiple myeloma...

Full description

Bibliographic Details
Main Authors: Slavisa Ninkovic, Simon J Harrison, Je-Jung Lee, Nick Murphy, Jae Hoon Lee, Jane Estell, Vivien M Chen, Noemi Horvath, Kihuyn Kim, Richard Eek, Bradley Augustson, Soo-Mee Bang, Shang-Yi Huang, Rajeev Rajagopal, Ferenc Szabo, Daniel Engeler, Belinda E Butcher, Peter Mollee, Brian Durie, Wee Joo Chng, Hang Quach
Format: Article
Language:English
Published: Ferrata Storti Foundation 2024-01-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11411

Internet

https://haematologica.org/article/view/11411

Similar Items